2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Rationale and design of the women's ischemia syndrome evaluation mechanisms of coronary microvascular dysfunction leading to preheart failure with preserved ejection fraction (WISE Pre-HFPEF)

BACKGROUND

There is increasing recognition that the pathophysiology of coronary microvascular dysfunction (CMD) plays a pivotal role in the development of heart failure with preserved ejection fraction (HFpEF). However, the mechanisms underlying this role are not known.

STUDY DESIGN AND METHODS

The Women's Ischemia Syndrome Evaluation Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (WISE Pre-HFpEF) is a prospective cohort study enrolling 180 women and men undergoing clinically indicated invasive coronary angiography for suspected ischemia with no obstructive coronary artery disease. The study aims to investigate (1) CMD-related ischemia contribution to myocellular damage and impaired left ventricular (LV) relaxation as determined invasively by ultra-high sensitivity cardiac troponin I (u-hs-cTnI) measurements in the coronary sinus/great cardiac vein and LV pressure-volume loops, respectively, during provocative stress testing with isometric handgrip, and (2) CMD-related ischemic myocellular damage contribution to LV diastolic dysfunction progression as assessed using cardiac magnetic resonance imaging obtained at enrollment and 1-2 years later, along with prospectively repeated ambulatory u-hs-cTnI measurements.

CONCLUSIONS

The WISE pre-HFpEF study is designed to investigate whether ischemic myocardial damage secondary to CMD contributes to the progression of LV diastolic dysfunction. The findings from this study will provide new understanding of the role of CMD in HFpEF development as well as the potential benefits of CMD-directed therapies for the prevention and treatment of HFpEF.

TRIAL REGISTRATION

ClilicalTrial.gov, NCT03876223.

A 7-year feed study on the long-term effects of genetically modified maize containing cry1Ab/cry2Aj and EPSPS genes on gut microbiota and metabolite profiles across two generations of cynomolgus macaques

The health implications of genetically modified (GM) crops remain controversial relative to their non-GM counterparts, particularly regarding long-term dietary exposure. Although the gut microbiome is a key health indicator, studies investigating the impact of GM crop consumption on intestinal microbiota remain limited. This study presents a comprehensive 7-year evaluation of GM maize expressing cry1Ab/cry2Aj and G10evo-EPSPS proteins through metagenomic and metabolomic analyses. We assessed the effects of GM maize consumption on gut microbiota diversity and metabolite profiles in cynomolgus macaques (Macaca fascicularis) compared with non-GM maize. Three diet regimens were implemented: a conventional compound feed (CK group), diet formulation containing 70 % non-GM maize (Corn group), and diet formulation containing 70 % GM maize (Tg group). The results demonstrated that feeding GM maize to the first (F0) and second (F1) generations of monkeys did not substantially affect the composition, community structure, or function of the intestinal microbiome, as indicated by species composition and diversity analyses. Minor differences in intestinal metabolites were observed but were not directly linked to transgenic maize consumption. Collectively, long-term intake of maize with cry1Ab/cry2Aj and g10evo-epsps genes had no adverse effects on macaques or their offspring.

Positive correlation between n- 6 : n- 3 PUFA ratio intake with serum oxHDL/HDL-c ratio in patients with coronary artery disease

BACKGROUND

Coronary artery disease (CAD) is one of the most prevalent cardiovascular diseases where serum lipoprotein oxidation plays a significant role. Polyunsaturated fatty acids (PUFA) n -6 :  n -3 unbalance ratio consumption, affects lipoprotein oxidation, and inflammation processes. This study aimed to analyze the relationship between n -6 :  n -3 PUFA ratio intake with oxidized lipoproteins in individuals with CAD.

METHODS

A cross-sectional study was performed including 105 subjects (51 diagnosed with CAD and 54 non-CAD) from western Mexico. Dietary information was collected using a habitual day food record. Serum oxidized low-density lipoprotein (oxLDL) and oxidized high-density lipoprotein (oxHDL) concentrations were quantified by enzyme linked immunosorbent assay.

RESULTS

CAD subjects had higher oxHDL/HDL cholesterol (HDL-c) ratio [0.102 (0.092-0.112) vs. 0.080 (0.070-0.090), P  = 0.004] and oxLDL/LDL cholesterol (LDL-c) ratio [129.2 (108-150.4) vs. 59.7 (39.3-80), P  < 0.001] compared to non-CAD subjects. Risk factors associated with CAD were a high n -6 :  n -3 PUFA ratio (odds ratio, OR = 2.3, P  = 0.046), hypoalphalipoproteinemia in men (OR = 3.2, P  = 0.014), moderate/high tobacco index (OR = 6.33, P  = 0.003), elevated waist circumference in women (OR = 7, P  = 0.004), hypertension (OR = 21.14, P  < 0.001), and type 2 diabetes (OR: 25, P  < 0.001). The oxHDL/HDL-c ratio was positively associated with the n -6 :  n -3 PUFA ratio [ r2  = 28.3, B  = 0.002 (0.001-0.003), P  < 0.001] in CAD patients.

CONCLUSIONS

This study showed that a higher n -6 :  n -3 PUFA ratio intake correlates with higher serum oxHDL/HDL-c in CAD patients.

Key predictors of long-term survival after lung transplantation in Japan

BACKGROUND

Lung transplantation (LTx) is essential for treating end-stage lung diseases in Japan, achieving favorable long-term survival despite donor shortages. However, factors associated with long-term survival after transplantation remain unclear. This study aims to identify key predictors influencing post-transplant outcomes.

METHODS

A retrospective analysis was conducted on LTx recipients at Tohoku University Hospital from 2000 to 2019, with a follow-up period of five years to 2024. Recipients were categorized into short survivors (<5 years) and long survivors (≥5 years). The analysis focused on recipient demographics, donor characteristics, surgical factors, and post-transplant outcomes.

RESULTS

Of 124 recipients, 36 were short survivors, and 88 were long survivors. Long-term survivors were younger, with a lower prevalence of patients aged 55 years and older. Additionally, fewer long-term survivors received lungs from critically marginal donors compared to short-term survivors. CMV serology was a significant factor, with a higher incidence of CMV disease observed in short-term survivors.

CONCLUSION

The study identified younger age, selective donor use, and CMV status as key predictors associated with long-term survival after LTx in Japan. The findings underscore the importance of targeted CMV management strategies and suggest that future multicenter studies with larger, more diverse populations are needed to confirm these results and further enhance long-term survival outcomes.

Cardiac Rehabilitation for Women with Heart Disease

Cardiovascular disease is the leading cause of morbidity and mortality in women globally. Cardiac rehabilitation (CR)-a comprehensive program including supervised progressive exercise, education, support, behavior modification, and nutritional guidance over 36 individual sessions-positively impacts morbidity, mortality, function, and quality of life. Overall, less than 30% of those who qualify are referred and participate in CR-referral and completion rates are significantly less in women compared with men despite evidence supporting equal benefit. Barriers contributing to these disparities have been identified, and CR programs can be modified to enhance the participation of women.

Machine Learning-Based Prediction Models for Healthcare Outcomes in Patients Participating in Cardiac Rehabilitation: A Systematic Review

PURPOSE

Cardiac rehabilitation (CR) has been proven to reduce mortality and morbidity in patients with cardiovascular disease. Machine learning (ML) techniques are increasingly used to predict healthcare outcomes in various fields of medicine including CR. This systemic review aims to perform critical appraisal of existing ML-based prognosis predictive model within CR and identify key research gaps in this area.

REVIEW METHODS

A systematic literature search was conducted in Scopus, PubMed, Web of Science, and Google Scholar from the inception of each database to January 28, 2024. The data extracted included clinical features, predicted outcomes, model development, and validation as well as model performance metrics. Included studies underwent quality assessments using the IJMEDI and Prediction Model Risk of Bias Assessment Tool checklist.

SUMMARY

A total of 22 ML-based clinical models from 7 studies across multiple phases of CR were included. Most models were developed using smaller patient cohorts from 41 to 227, with one exception involving 2280 patients. The prediction objectives ranged from patient intention to initiate CR to graduate from outpatient CR along with interval physiological and psychological progression in CR. The best-performing ML models reported area under the receiver operating characteristics curve between 0.82 and 0.91, with sensitivity from 0.77 to 0.95, indicating good prediction capabilities. However, none of them underwent calibration or external validation. Most studies raised concerns about bias. Readiness of these models for implementation into practice is questionable. External validation of existing models and development of new models with robust methodology based on larger populations and targeting diverse clinical outcomes in CR are needed.

The Predictive Value of Preoperative Coronary Artery Calcium Score for Long-term Survival in Elderly Patients with Lung Cancer After Surgery

BACKGROUND

A large proportion of elderly lung cancer patients have coronary atherosclerosis. However, it remains unclear which coronary artery indicators provide optimal prognostic value for elderly patients with lung cancer after surgery.

METHODS

This study retrospectively analyzed the clinical data of elderly patients with lung cancer who underwent surgery between September 2013 and September 2021. Three coronary artery indicators including the severity of coronary artery stenosis, coronary artery calcium score (CACS), and computed tomography-derived fractional flow reserve (CT-FFR) and clinical data were evaluated. The Cox proportional hazards model and competing risk model were used to identify independent prognostic factors for all-cause death and non-lung cancer death, respectively. Based on these factors, a nomogram was developed and validated to predict the overall survival of elderly patients with lung cancer after surgery. The performance of the nomogram was evaluated using the concordance index, receiver operating characteristic curve, calibration curve, and decision curve analysis.

RESULTS

The study finally included 896 elderly patients with lung cancer, randomly divided into training group (n=627) and validation group (n=269) in a 7:3 ratio. Among the three coronary artery indicators, only CACS >40 affected the long-term survival of elderly patients with lung cancer after surgery, especially for those who underwent lobectomy, but had no effect on those undergoing sublobar resection. Age, smoking, %dynamic diffusion lung capacity of carbon monoxide (DLCO), CACS >40, surgical procedure, pathological stage, and pathological type were identified as independent prognostic factors for all-cause death. Smoking and CACS >40 were identified as independent risk factors for non-lung cancer death. The nomogram incorporating CACS exhibited robust predictive performance.

CONCLUSION

This study shows that CACS has a significant predictive value for all-cause death and non-lung cancer death in elderly lung cancer patients after surgery. For elderly lung cancer patients with high CACS, sublobar resection may improve their survival compared to lobectomy.

Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association

The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice. First, the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America HF guidelines provided recommendations, for the first time, on the clinical utility of multivariable risk equations to estimate risk of incident HF. Second, the American Heart Association recently developed the PREVENT (Predicting Risk of Cardiovascular Disease Events) equations, which not only enable prediction of incident HF separately, but also include HF in the prediction of total cardiovascular disease. Third, the predominant phenotype of HF risk has emerged as the cardiovascular-kidney-metabolic syndrome. Fourth, the emergence of novel therapies that prevent incident HF (eg, sodium-glucose cotransporter-2 inhibitors) and target multiple cardiovascular-kidney-metabolic axes demonstrate growing potential for risk-based interventions. Whereas the concept of risk-based prevention has been established for decades, it has only been operationalized for atherosclerotic cardiovascular disease prevention to date. Translating these opportunities into a conceptual framework of risk-based primary prevention of HF requires implementation of PREVENT-HF (Predicting Risk of Cardiovascular Disease Events-Heart Failure) equations, targeted use of cardiac biomarkers (eg, natriuretic peptides) and echocardiography for risk reclassification and earlier detection of pre-HF, and definition of therapy-specific risk thresholds that incorporate net benefit and cost-effectiveness. This scientific statement reviews the current evidence for accurate risk prediction, defines strategies for equitable prevention, and proposes potential strategies for the successful implementation of risk-based primary prevention of HF.

Impact of COPD on cardiovascular risk factors and outcomes in people with established cardiovascular disease

BACKGROUND

Little is known about the association between chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) in people with established CVD. Knowing if COPD is associated with a higher risk of cardiovascular events would guide appropriate secondary prevention.

OBJECTIVE

To examine the risk of COPD on major adverse cardiac events (MACEs, acute myocardial infarction, stroke and cardiovascular death) in a complete real-world population of a large province, with known CVD.

METHODS

We conducted a retrospective population cohort study using health administration, medication, laboratory, electronic medical record and other data from Ontario, Canada. All people with a history of CVD with and without physician-diagnosed COPD as of 2008 were followed until 2016 and cardiac risk factors, sociodemographic factors, comorbidities and other factors were compared. Sequential cause-specific hazard models adjusting for these factors determined the risk of MACE in people with COPD.

RESULTS

Of 496 056 individuals with CVD in Ontario on 1 January 2008, 69 161 (13.9%) had COPD. MACE occurred more frequently among those with CVD (45.3 per 1000 person-years) and COPD compared with those with CVD alone (28.6 per 1000 person-years) (HR 1.24, 95% CI 1.21-1.26) after adjustment for cardiac risk factors, comorbidities, socioeconomic status and other factors. People with COPD were less likely to receive preventive CVD medications or see a cardiologist.

CONCLUSION

In a large, real-world population of people with established CVD, COPD was associated with a higher rate of cardiovascular events but a lower rate of preventive therapy. Strategies are needed to improve secondary CVD prevention in the COPD population.

First-pass perfusion imaging using cardiovascular magnetic resonance in patients with various cardiac implantable electronic devices

AIMS

The number of patients with cardiac implantable electronic devices (CIEDs) is increasing. However, there is limited experience regarding vasodilator-stress cardiovascular magnetic resonance (CMR) and resulting device artifacts on perfusion images. The aim of this study was to determine CMR image quality in patients with different CIED types for CMR-based perfusion stress testing.

METHODS AND RESULTS

A total of 156 patients with active CIEDs underwent CMR on a 1.5-Tesla scanner. Both conventional steady-state-free-precession (SSFP) and modified spoiled gradient-echo (sGE) protocols under stress and resting conditions were used to evaluate image artifacts in a 16-segment segment model of the heart. The study group comprised 39% conventional pacemaker (PM), 4% cardiac resynchronization therapy-pacemaker (CRT-P), 38% conventional implantable cardioverter-defibrillator (ICD), 6% cardiac resynchronization therapy-ICD (CRT-D), and 13% subcutaneous ICD (S-ICD) patients. PM-carriers showed only minor image artifacts in both perfusion protocols. Artifacts caused by ICDs were predominantly located in the left-ventricular (LV) inferolateral and anterior segments. S-ICDs showed the highest extent of artifacts with an anterolateral accentuation. The artifact extent was significantly reduced when sGE-based perfusion was used compared to SSFP-based sequences. 69% of the patients received a stress-perfusion protocol, and elective coronary angiography confirmed the presence of coronary stenosis in three cases. No major safety-relevant issues occurred.

CONCLUSION

Myocardial perfusion imaging by CMR is safe and feasible with moderate-to-high image quality in patients with all types of CIEDs, including non-conditional devices, ICDs, and S-ICDs. A sGE-based perfusion protocol should be preferred in patients with left-sided ICDs, CRT-Ds, or S-ICDs.

Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence

PURPOSE

Despite improvements in the secondary prevention of atherothrombosis in patients with coronary artery disease during the past decade, it is estimated that approximately 19 million people annually die from cardiovascular diseases worldwide. Atherothrombosis remains the core pathobiology of acute complications including myocardial infarction (MI), and therefore, antithrombotic therapy plays a pivotal role in the strategies for major adverse cardiovascular event (MACE) prevention. Unlike early antithrombotic management after acute coronary syndrome, less evidence is available on long-term antithrombotic therapy in patients with chronic coronary syndrome (CCS). In addition, greater recognition of the impact of bleeding complications of such therapies has led to a more complex and personalized approach to their application. The purpose of this article is to review the available evidence on long-term antithrombotic therapy in patients with CCS including those with high-risk characteristics such as prior MI or polyvascular disease.

METHODS

A comprehensive literature review was performed in major databases including PubMed, Embase, and the Cochrane Library. The main focus of this narrative review was on available data from guidelines, meta-analysis, randomized controlled trials, and observational studies that assessed the efficacy and safety profile of long-term antithrombotic therapy in patients with CCS.

FINDINGS

Several studies suggest that long-term antithrombotic therapy is effective in reducing the risk of recurrent MACEs in patients with CCS. Current clinical guidelines recommend single antiplatelet therapy with aspirin as a first-line long-term strategy for patients without indication for oral anticoagulation. However, novel approaches focused on P2Y12 inhibitor monotherapy are emerging. More intensive antithrombotic strategies including long-term dual antiplatelet therapy and dual pathway inhibition further reduce ischemic risk but at the cost of increased bleeding.

IMPLICATIONS

This review highlights the importance of close monitoring and regular reassessment of the risk-benefit balance of antithrombotic therapy in patients with CCS. Overall, long-term antithrombotic therapy with either single antiplatelet therapy or dual antiplatelet therapy/dual pathway inhibition is effective in reducing the risk of MACEs in patients with CCS. The choice of antithrombotic therapy should be individualized based on the patient's clinical profile, particularly for thrombohemorrhagic risk. Future research should focus on identifying the optimal antithrombotic regimen for specific subgroups of patients with prior MI particularly for those with high bleeding risk.

Patient-centric no-option refractory angina management: establishing comprehensive angina relief (CARE) clinics

INTRODUCTION

Refractory angina (RA) is a debilitating condition characterized by persistent angina despite optimized medical therapy and limited options for further revascularization, leading to diminished quality of life and increased healthcare utilization. The RA patient population is rapidly expanding with significant unmet needs. Specialty clinics should be developed to focus on the long-term efficacy and safety of clinically available and novel treatment strategies, emphasizing quality of life.

AREAS COVERED

Patient-focused Comprehensive Angina Relief (CARE) clinics can enhance care and outcomes by providing individualized management for complex RA. This review summarizes peer-reviewed articles from PubMed and trial data from ClinicalTrials.gov. We discuss the epidemiology and pathophysiology of RA, introduce standardized tools for evaluating angina and psychosocial factors, and address symptom management. We also review treatment options such as risk factor modification, medication, and complex revascularization. Additionally, we explore emerging therapies, including coronary sinus occlusion, regenerative therapy, and neuromodulation for 'no-option' RA.

EXPERT OPINION

In the next five years, patients with refractory chest pain with or without coronary artery disease will increasingly be referred to specialty clinics for follow-up. Conducting more randomized control clinical trials with larger population subsets will bring novel therapies to the forefront.

Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks

PURPOSE OF REVIEW

Renin-angiotensin-aldosterone system inhibitors (RAASi), including angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), are fundamental in chronic kidney disease (CKD) management, particularly in proteinuric conditions. However, their use in advanced CKD (eGFR <30 ml/min/1.73 m 2 ) remains debated because of risks of hyperkalaemia, acute kidney injury (AKI), and hypotension. This review evaluates the latest evidence, including the STOP-ACEi trial, to inform the risks and benefits of RAASi in advanced CKD.

RECENT FINDINGS

The STOP-ACEi trial, a multicentre randomized controlled trial (RCT), investigated RAASi discontinuation in 411 patients with advanced CKD. After 3 years, discontinuation did not slow eGFR decline or reduce mortality, while continuation was associated with a numerical trend towards lower end-stage kidney disease (ESKD) rates. Meta-analyses also indicate that ACEi may offer superior kidney protection compared to ARBs, though both lower cardiovascular risk and this difference may not be clinically significant. Combination ACEi/ARB therapy provides no additional benefits and increases adverse events, such as hyperkalaemia and hypotension. Adjunct therapies like potassium binders and sodium-glucose cotransporter-2 (SGLT2) inhibitors may enable safer RAASi use in high-risk patients.

SUMMARY

Current evidence supports RAASi continuation in most CKD patients, including those with advanced disease, unless contraindicated. Future studies should refine patient selection criteria and optimize adjunctive strategies to mitigate adverse effects.

Determinant factors of prolonged hospitalization in acute heart failure patients at Jimma Medical Center, Southwest Ethiopia

Millions of people worldwide suffer from heart failure, which is a serious public health concern that results in high medical costs from prolonged hospital stay. This study aimed to assess the determinant factors associated with prolonged hospitalization among admitted acute heart failure at Jimma Medical Center, south west Ethiopia. The study was conducted at Jimma Medical Center in Ethiopia from December 2023 to April 2024, employing a prospective observational design. Statistical analysis was performed using Epi-data V.4.6 and STATA V.17 and multiple linear regression was employed. T test and ANOVA were conducted and a p-value is deemed significant if it is less than 0.05, corresponding to a 95% confidence interval. A total of 294 individuals were enlisted, with a mean age of 56. Over half of the patients (53.4%) stayed eight days or more throughout their average 11.4-day hospital stay. The following were significant risk factors for extended hospital stays: living in a rural; being admitted to a cardiac unit having neck vein distension, having a third heart sound, having ankle edema; having hepatomegaly, and having pleural effusion were predictor's of length of hospital stay. Based on this finding, the length of hospital stay in heart failure patients is influenced by various factors. Addressing these factors can help reduce the duration of hospitalization. Implementing targeted interventions, such as improving physical activity, managing comorbidities, and enhancing discharge planning, may lead to better patient outcomes and decrease the prolongation of hospital stays for those with heart failure.

Myocardial Revascularization in Patients with Diabetes and Heart Failure-A Narrative Review

Heart failure and diabetes mellitus are major contributors to global morbidity and mortality, with their prevalence continuously rising, primarily due to aging populations and improvements in healthcare. These conditions often coexist or develop sequentially, leading to complex interactions that significantly influence the progression and management of both diseases. Furthermore, heart failure and diabetes are commonly associated with coronary artery disease, which presents a unique challenge in clinical management, particularly in the context of myocardial revascularization. The presence of diabetes exacerbates atherosclerotic progression and impairs endothelial function, while heart failure complicates the perfusion and recovery of myocardial tissue post-intervention. This narrative review delves into the underlying mechanisms contributing to revascularization failure in patients with heart failure and diabetes, emphasizing the importance of understanding these interactions for optimal treatment. The review also summarizes key findings from randomized controlled trials, examining evidence both in the general population and in specific subgroups, including the elderly and patients with left main coronary artery disease, chronic kidney disease, peripheral artery disease, and chronic obstructive pulmonary disease. Understanding these complexities is critical for improving patient outcomes.

Motion-unrestricted dynamic electrocardiogram system utilizing imperceptible electronics

Electrocardiogram (ECG) plays a vital role in the prevention, diagnosis, and prognosis of cardiovascular diseases (CVDs). However, the lack of a user-friendly and accurate long-term dynamic electrocardiogram (DCG) device in motion has made it challenging to perform many daily cardiovascular risk screenings and assessments, such as sudden cardiac arrest, resulting in additional economic burdens on society. Here, we present a motion-unrestricted dynamic electrocardiogram (MU-DCG) system, which employs skin-conformal, imperceptible electronics for long-term, comfortable, and accurate 12-lead DCG monitoring. To facilitate assembly for use on the skin, the MU-DCG system features a pressure-activated flexible skin socket for stably soft-connecting the on-skin soft module and the off-skin stiff module during dynamic movements. Crucially, blinded cardiologist evaluations confirm minimal motion artifacts in MU-DCG-acquired ECG signals. Our results demonstrate that the MU-DCG system, with large-area, ultra-thin on-skin electrodes/leads, and an off-skin module, accomplishes anti-motion interference acquisition and in-situ analysis while retaining wearing imperceptibility.

Coronary Angiography in the Evaluation of Systolic Heart Failure

The review discusses angiographic and hemodynamic features of invasive and computed tomography coronary angiography, which inform diagnosis, prognosis, and coronary revascularization in patients with systolic heart failure.

Turkish version of the German Eating Behavior Scale (SEV-Tr): a study of reliability and construct validity

This two-phase study aims to develop the Turkish version of the German Eating Behavior Scale (SEV-Tr), and to investigate the potential associations of health-conscious and weight-controlling eating behaviors with nutritional and health status. In the first phase, the original scale was adapted to the Turkish language and its validity and reliability were assessed in 299 healthy individuals aged 19-64 years. In the second phase, the SEV-Tr was retested in a study population of 110 healthy individuals, aged 19-64 years, and the potential associations between the SEV-Tr score, anthropometrical and biochemical measurements, and other eating behaviors assessed by the Three-Factor Eating Questionnaire (TFEQ-Tr21) were examined. Statistical analyses were performed using AMOS 20.00 and SPSS 22.0 software packages. A two-dimensional structure was identified for the SEV-Tr, and named 'health-conscious eating behavior' and 'weight- controlling eating behavior'. In the second phase, participants were clustered based on their weight-controlling and health-conscious eating behaviors (F = 59.46, p = 0.01). Participants with lower health-conscious and weight-controlling eating behaviors had higher lean body mass (p = 0.03), serum triglyceride levels (p = 0.01), emotional eating behavior (p = 0.03), and lower cognitive restraint behavior (p = 0.01, p < 0.05). Furthermore, participants with high levels of health-conscious eating behavior had higher serum HDL cholesterol (r = 0.23, p = 0.02). Regression models suggested that lower levels of emotional eating and higher levels of cognitive restraint were associated with increased weight-controlling and health-conscious eating behaviors. This study provided a valid and reliable version of the SEV to assess the health-conscious and weight-controlling eating patterns in people from Turkish culture.

Combined assessment of fractional flow reserve, resting full-cycle ratio, and resting ratio of distal coronary to aortic pressure for clinical outcomes

BACKGROUND

Fractional flow reserve (FFR) and non-hyperemic indices are invasive standards for evaluating functional significance of coronary stenosis. However, data are limited about outcomes in vessels with concordant and discordant physiological results, particularly with a ratio of distal coronary to aortic pressure (Pd/Pa) at rest.

METHODS

This was a single-center, retrospective, observational study. Coronary physiological indices including FFR, resting full-cycle ratio (RFR), and resting Pd/Pa were invasively evaluated in vessels with intermediate coronary artery stenosis. FFR ≤0.80, RFR ≤0.89, and resting Pd/Pa ≤0.92 were considered physiologically positive. Vessels were divided into three groups according to the results of FFR, RFR, and resting Pd/Pa: concordant positive (all positive for FFR, RFR, and resting Pd/Pa), concordant negative (all negative for FFR, RFR, and resting Pd/Pa), and discordant groups. The primary endpoint was target vessel failure (TVF) defined as a composite of cardiac death and target vessel myocardial infarction and unplanned revascularization.

RESULTS

Of 987 vessels included, 311 (31.5 %), 263 (26.6 %), and 413 (41.9 %) were in the concordant positive, discordant, and concordant negative groups. During a median follow-up period of 417 (208-756) days, TVF occurred more frequently in the concordant positive group, followed by the discordant and concordant negative groups (7.7 % vs. 4.6 % vs. 2.4 %, p = 0.004). TVF increasingly accrued during long-term follow-up, while discordant results of RFR and resting Pd/Pa did not result in worse outcomes compared with negative RFR and resting Pd/Pa.

CONCLUSION

The combined assessment of FFR with RFR and resting Pd/Pa stratified TVF risks in vessels with intermediate coronary stenosis.

Combined single-photon emission computed tomography-myocardial perfusion imaging with coronary calcium score for assessing coronary disease

PURPOSE

Coronary artery disease (CAD) underestimation represents a major pitfall of single-photon emission computed tomography-myocardial perfusion imaging (SPECT-MPI). Coronary artery calcium score (CACS) has emerged as a sensitive tool for the assessment of suspect CAD; however, the integration of SPECT-MPI with CACS has been seldom evaluated, so far, and was therefore the aim of the present study.

METHODS

Patients undergoing SPECT-MPI with CACS and subsequent coronary angiography were included. ROC curves were used to identify the CACS values best predictive for CAD. In SPECT-MPI negative patients, the formula: defined the optimal CACS cut-points. The Systematic Coronary Risk Evaluation 2 was applied for 10-year cardiovascular risk estimation. Significant CAD was defined for an epicardial coronary stenosis >70 or 50% for the left main.

RESULTS

Among 124 patients, 61 (49.19%) displayed positive SPECT-MPI, whereas 69 (56%) had significant CAD at angiography. Sensitivity, specificity, and positive predictive value (PPV) for SPECT-MPI were, respectively, 74, 82, and 84%. Considering 63 SPECT-MPI negative cases, the index values for CACS at the optimal cutoff value of 1949 were: sensitivity 28%, specificity 89%, and PPV 50%, allowing to further detect five (8%) of the patients with significant CAD. The increased discriminative power of the combined SPECT-MPI with CACS was not conditioned by the pretest cardiovascular risk.

CONCLUSION

Among patients with suspect CAD undergoing SPECT-MPI, the addition of CACS in negative cases allows to detect a consistent further 8% of patients with significant CAD, thus limiting the risk of disease underestimation and offering potential prognostic benefits.

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

AIM

The "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes" incorporates new evidence since the "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction" and the corresponding "2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes" and the "2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction." The "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes" and the "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization" retire and replace, respectively, the "2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease."

METHODS

A comprehensive literature search was conducted from July 2023 to April 2024. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.

STRUCTURE

Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.

The prognostic value of preoperative CAD-RADS classification in patients undergoing isolated aortic valve surgery

To investigate the association between preoperative coronary artery disease (CAD) severity, as classified by the Coronary Artery Disease Reporting and Data System (CAD-RADS), and clinical outcomes in patients undergoing isolated aortic valve replacement (AVR). A total of 897 patients (452 women; mean age, 66.1 ± 9.3 years) who underwent isolated AVR and preoperative coronary computed tomography angiography (CCTA) between 2004 and 2022 were stratified by the CAD-RADS score. The outcomes of interest were all-cause death and major adverse cardiac and cerebrovascular events (MACCE). The CAD-RADS score was 0 in 290 (32%) patients, 1 in 208 (23%), 2 in 255 (29%), 3 in 82 (9%), and 4 in 62 (7%) patients. The rates of all-cause death and MACCE tended to increase in parallel with CAD-RADS score (4%, 10.5%, 8.2%, 18.2%, 28.1% at 5 years and 14.4%, 15.1%, 16.7%, 26.9%, 38.4% at 5 years, both P < 0.001). CAD-RADS score ≥ 3 was associated with a higher risk of all-cause death (HR 2.44, 95% CI: 1.52-3.93) and MACCE (HR 1.79, 95% CI: 1.27-2.52) after adjusting for potential confounders. Notably, patients with CAD-RADS ≥ 3 who received medical therapy in addition to coronary angiography (CAG) improved overall survival compared to those who did not undergo CAG. Preoperative CCTA with CAD-RADS assessment would be useful for screening concomitant CAD and predicting long-term clinical outcomes including all-cause death and MACCE in patients undergoing isolated AVR. For patients with CAD-RADS ≥ 3, it is essential to implement medicinal therapy or intervention along with CAG.

Coronary Microvascular Dysfunction: Identification, Special Populations, and Management Strategies

Coronary microvascular dysfunction (CMD) is a prevalent and often underdiagnosed condition with significant implications for adverse cardiovascular outcomes. The pathophysiology of CMD includes structural and functional abnormalities in the coronary microvasculature and epicardial atherosclerosis contributes to downstream reduction in myocardial perfusion and symptoms. Diagnosis relies on advanced invasive or noninvasive imaging techniques, such as PET and cardiac magnetic resonance, capable of quantifying myocardial perfusion and myocardial blood flow reserve. Effective management includes optimizing cardiovascular risk factors and symptom control. Novel therapeutic strategies recently approved for management of diabetes, obesity, and heart failure with preserved ejection fraction offer potentially powerful options for management of CMD.

Medical Nutrition Therapy (MNT) Evidence Update: Comparative Effectiveness of Dietary Programs for Reducing Mortality and Cardiovascular Events in Adults with Increased Cardiovascular Disease Risk

HEALTH SERVICES QUESTION

In adults with established cardiovascular disease (CVD) risk factors, as compared with minimal intervention, what is the most effective dietary program intervention, with or without pharmacological management, physical activity, and behavioral support cointerventions, for reducing risk of early mortality and major cardiovascular events based on the best available systematic review and network meta-analyses of randomized clinical trials (RCTs)?

BOTTOMLINE

Based on 40 RCTs evaluating 7 dietary programs, moderate certainty evidence suggests that Mediterranean dietary programs (for example, high in vegetables, fruits, extra virgin olive oil, nuts, legumes, and fish), accompanied by varying cointerventions including pharmacological management (for example, statins), physical activity and behavioral support (for example, nutrition education, smoking cessation, and stress management), were superior to minimal interventions for reducing risk of all cause [1.7% absolute risk reduction (ARR)], cardiovascular mortality (1.3% ARR), stroke (0.7% ARR), and myocardial infarction (1.7% ARR) in patients with established CVD risk factors (for example, obesity, hypertension, dyslipidemia, or a previous cardiovascular event) over a 5-y period. Results from randomized trials with food provisions (for example, extra virgin olive oil, mixed nuts, primarily walnuts) among those living in Mediterranean regions had the largest treatment effects. Similarly, moderate certainty evidence demonstrated that low-fat dietary programs (for example, 20-30% total fat, <10% saturated fat, and high in fish, vegetables, and fruits together with varying cointerventions) were superior to minimal intervention for reducing all-cause mortality (0.9% ARR) and myocardial infarction (0.7% ARR) based on trials conducted in Mediterranean, North American, and Northern European regions. Network metaregression did not detect statistically significant differences in estimates when controlling for the presence of pharmacological management, physical activity, and behavioral support.

Approaches for Embedding Structural Competency and Social Determinants of Health in Pharmacy Curricula

There is emerging scholarship related to teaching social determinants of health (SDOH) in pharmacy education; however, challenges remain for pharmacy educators due to a lack of formal consensus on which aspects of SDOH should be taught or evaluated. SDOH is often confused with similar, overlapping concepts such as cultural competence, cultural humility, Diversity, Equity, and Inclusion; however, there are key differences. While all domains of SDOH are relevant to patient health outcomes, educators may find it challenging to determine which competencies are most essential for student pharmacists and most applicable to direct patient care in pharmacy practice. This article reviews literature from pharmacy and multiple health professions disciplines relating to teaching SDOH. The objective of this paper is to use this literature as support and leverage the expertise within the American Association of Colleges of Pharmacy (AACP) Health Disparities and Cultural Competence Special Interest Group, to provide guidance to pharmacy programs aiming to meet accreditation requirements. The recommendations herein are evidence-based, with practical insights and recommendations from forward-thinking pharmacy educators.

Diagnosing and treating stable angina: a contemporary approach for practicing physicians

Longer life expectancy and advancements in coronary artery disease management have improved life expectancy and survival, increasing the prevalence of chronic coronary syndromes (CCS). Angina is a common symptom in patients with CCS but remains underdiagnosed and undertreated. Contemporary guidelines provide detailed information on diagnosing and treating angina based on evidence and expert consensus; however, their extensive nature may hinder uptake by non-specialists. This review presents a practical approach to diagnosing stable angina, followed by the three pillars of CCS management: 1) healthy lifestyle including appropriate exercise, diet, and avoiding toxic habits; 2) optimal medical therapy, including treatment recommended to prevent cardiovascular events and drugs for the control of myocardial ischemia and angina tailored to the patient's comorbidities; and 3) myocardial revascularization when indicated. This approach may be useful for practicing physicians but is not intended to substitute more detailed and authoritative documents. Checklists are proposed to help focus patient-physician interactions and make follow-up visits more efficient. This approach seeks to increase the proportion of correct angina diagnoses and patients receiving evidence-based treatments, emphasizing the importance of patient education, managing residual angina, and reducing cardiovascular risk. We include reference to the recently published 2024 ESC guidelines on chronic coronary syndromes.

Are Hair Scalp Trace Elements Correlated with Atherosclerosis Location in Coronary Artery Disease?

Coronary artery disease is among the leading current epidemiological challenges. The genetic, clinical, and lifestyle-related risk factors are well documented. The reason for specific epicardial artery locations remains unsolved. The coronary artery topography and blood flow characteristics may induce local inflammatory activation. The atherosclerotic plaque formation is believed to represent inflammatory response involving enzymatic processes co-factored by trace elements. The possible relation between trace elements and coronary artery disease location was the subject of the study. There were 175 patients (107 (61) men and 68 (39) females) in a median (Q1-3) age of 71 years (65-76) admitted for coronary angiography due to chronic coronary syndrome. The angiographic results focused on the percentage of lumen stenosis in certain arteries and were compared with the results for hair scalp trace elements. The correlation between left main coronary artery atherosclerotic plaques and nickel (Ni), zinc (Zn), and antimony (Sb) hair scalp concentration was noted. The analysis revealed a positive relation between left descending artery disease and chromium (Cr), sodium (Na), arsenic (As), and molybdenum (Mo) and a negative correlation with strontium (Sr). The atherosclerotic lesion in the circumflex artery revealed correlations in our analysis with sodium (Na), potassium (K), chromium (Cr), nickel (Ni), arsenic (As), and negative with strontium (Sr) (r) hair scalp concentrations. The negative correlations between right coronary artery disease and magnesium (Mg) and strontium (Sr) concentrations were noted. The possible explanation of different epicardial artery involvement and severity by atherosclerotic processes may lay in their topography and blood rheological characteristics that induce different inflammatory reactions co0factored by specific trace elements. The trace element concentration in the hair scalp may correlate with a particular coronary atherosclerotic involvement, including the severity of lumen reduction. This may indicate the missing link between the pathophysiological processes of atherosclerosis development and its location in coronary arteries.

Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits

OBJECTIVE

To determine the prescribing rates of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) at cardiology, endocrinology, and primary care visits in a community health system.

PATIENTS AND METHODS

A cross-sectional study using electronic health record data from Bon Secours Mercy Health outpatient clinics across Virginia (2019, 2020, 2021) included patients 18 years and older with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD), and one or more outpatient visits. Adults with type 1 diabetes, stage 4/5 CKD, end-stage kidney disease, dialysis treatment, pregnancy, or hospice or palliative care were excluded. Prescribing rates were compared overall and for each subgroup among cardiology, endocrinology, and primary care visits using generalized linear mixed modeling with a random practice-level effect.

RESULTS

The 22,060 included patients had a mean age of 68 years, 50% were female (n=11,030), 41.3% were Black race (n=9,100), and 74.8% were Medicare beneficiaries (n=16,498). In addition, 17,724 patients (80.3%) had ASCVD, 5276 (23.9%) CKD, and 5,965 (27.0%) HF. Overall, prescriptions for either drug class occurred in 17.4% of eligible patients (n=3,849). Cardiology visits had the lowest prescribing rates overall and for each diagnosis subgroup compared with endocrinology and primary care visits in the raw, unadjusted, and adjusted models.

CONCLUSION

Overall prescribing rates for SGLT2i and GLP-1 RA were low among adults with type 2 diabetes and ASCVD, HF, or CKD. Additional research is warranted to identify barriers, and potential solutions, to improve prescribing of these therapies.

Elimination of artifacts caused by residual radiopharmaceutical activity in injection site in myocardial perfusion imaging on Discovery NM 530c semiconductor gamma camera

BACKGROUND

Cardiac gamma cameras dedicated for myocardial perfusion imaging (MPI) perform studies faster and acquire higher quality images than traditional cameras. However, they are susceptible to some artifacts. We observed a previously unreported artifact, caused by residual radiopharmaceutical activity in injection site in cubital fossa caught in camera field of view. This study aims to assess the impact of these artifacts on image quality and the possibility of their elimination. Study included 50 male patients referred for MPI using Discovery NM 530c gamma camera, in whom radiopharmaceutical activity in injection site was observed in stress or rest study. In such cases, image acquisition was immediately repeated, with the patient and the camera kept in the same position, after covering the injection site with a special lead shield. Obtained images were assessed by two experienced nuclear medicine physicians using a 0-4 point scale in each segment (where 0-normal perfusion, and 4-complete lack of perfusion). Summed stress, rest and difference scores (SSS, SRS and SDS, respectively) were calculated for the entire myocardium and 3 main vascular territories.

RESULTS

SSS, SRS and SDS were most frequently assessed as abnormal in RCA territory. Radiopharmaceutical activity in injection site was observed more frequently in stress studies (84% of cases). Covering injection site with a shield changed the assessment of SSS, SRS or SDS from normal to abnormal and vice versa in almost 20% of studies. The most frequently affected vascular territories were LAD and RCA. Elimination of the artifact changed final diagnosis in almost 1/5 of patients, most often by eliminating previously visible significant stress-induced perfusion defects (patients in whom such change occurred did not report any cardiovascular events in one-year follow-up).

CONCLUSIONS

Artifacts caused by radiopharmaceutical activity in injection site reduce image quality and can potentially generate or hide perfusion defects. They can be observed mainly in patients examined in prone position, after radiopharmaceutical injection in cubital fossa. These artifacts can be eliminated by a lead shield, which can change the final assessment of MPI study in 20% of the patients.

The hypothalamic estrogen receptor α pathway is involved in high-intensity interval training-induced visceral fat loss in premenopausal rats

BACKGROUND

Visceral adipose tissue (VAT) is strongly associated with metabolic diseases. Both high-intensity interval training (HIT) and moderate-intensity training (MIT) reduce VAT effectively; however, HIT might mediate greater VAT loss in females. The estrogen receptor α (ERα) pathway may play a key role. The aim of the present study was to confirm the role of adipose/hypothalamic ERα in HIT/MIT-mediated VAT loss, as well as the associated hypothalamic electrophysiology and body catabolism changes in pre- and post-menopausal animal models.

METHODS

Ovariectomy (OVX) or sham surgeries were conducted to establish pre/postmenopausal female rat models. After distance-matched long-term HIT and MIT interventions, ERα expression in hypothalamic/VAT, as well as food intake, spontaneous physical activity (SPA), VAT mass and morphology, local field potential (LFPs) in paraventricular nuclei (PVN) and excessive post-exercise oxygen consumption (EPOC), were observed. A target chemical block during the post-exercise recovery period was executed to further verify the role of the hypothalamic ERα pathway.

RESULTS

HIT enhanced the expression of ERα in the hypothalamus rather than VAT in the pre-, but not the postmenopausal group, which was accompanied by elevated LFP power density in α and β bands, enhanced EPOC and larger VAT loss than MIT. Chemical blockade of ERα suppressed EPOC and VAT catabolism mediated by HIT.

CONCLUSION

During the post-exercise recovery period, the hypothalamic ERα pathway involved in HIT induced EPOC elevation and VAT reduction in premenopausal female rats.

Do Beta-Blockers Really Matter in Patients with Myocardial Infarction Without Left Ventricular Systolic Dysfunction? Comment on Sabina et al. Beta-Blockers in Patients with Myocardial Infarction and Preserved Left Ventricular Ejection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2025, 14, 150

Beta-blockers represent a key treatment pillar for reducing mortality and morbidity in patients with myocardial infarction (MI) and stable heart failure with a reduced ejection fraction (HFrEF) [...].

Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Metabolic-dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a highly prevalent metabolic disorder characterized by hepatic steatosis in conjunction with at least one cardiometabolic risk factor, such as obesity, type 2 diabetes, hypertension, or dyslipidemia. As global rates of obesity and metabolic syndrome continue to rise, MASLD is becoming a major public health concern, with projections indicating a substantial increase in prevalence over the coming decades. The disease spectrum ranges from simple steatosis to metabolic-dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma, contributing to significant morbidity and mortality worldwide. This review delves into the molecular mechanisms driving MASLD pathogenesis, including dysregulation of lipid metabolism, chronic inflammation, oxidative stress, mitochondrial dysfunction, and gut microbiota alterations. Recent advances in research have highlighted the role of genetic and epigenetic factors in disease progression, as well as novel therapeutic targets such as peroxisome proliferator-activated receptors (PPARs), fibroblast growth factors, and thyroid hormone receptor beta agonists. Given the multifaceted nature of MASLD, a multidisciplinary approach integrating early diagnosis, molecular insights, lifestyle interventions, and personalized therapies is critical. This review underscores the urgent need for continued research into innovative treatment strategies and precision medicine approaches to halt MASLD progression and improve patient outcomes.

Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes

BACKGROUND AND AIMS

Skeletal muscle (SM) fat infiltration, or intermuscular adipose tissue (IMAT), reflects muscle quality and is associated with inflammation, a key determinant in cardiometabolic disease. Coronary flow reserve (CFR), a marker of coronary microvascular dysfunction (CMD), is independently associated with body mass index (BMI), inflammation and risk of heart failure, myocardial infarction, and death. The relationship between SM quality, CMD, and cardiovascular outcomes is not known.

METHODS

Consecutive patients (n = 669) undergoing evaluation for coronary artery disease with cardiac stress positron emission tomography demonstrating normal perfusion and preserved left ventricular ejection fraction were followed over a median of 6 years for major adverse cardiovascular events (MACEs), including death and hospitalization for myocardial infarction or heart failure. Coronary flow reserve was calculated as stress/rest myocardial blood flow. Subcutaneous adipose tissue (SAT), SM, and IMAT areas (cm2) were obtained from simultaneous positron emission tomography attenuation correction computed tomography using semi-automated segmentation at the 12th thoracic vertebra level.

RESULTS

Median age was 63 years, 70% were female, and 46% were nonwhite. Nearly half of patients were obese (46%, BMI 30-61 kg/m2), and BMI correlated highly with SAT and IMAT (r = .84 and r = .71, respectively, P < .001) and moderately with SM (r = .52, P < .001). Decreased SM and increased IMAT, but not BMI or SAT, remained independently associated with decreased CFR (adjusted P = .03 and P = .04, respectively). In adjusted analyses, both lower CFR and higher IMAT were associated with increased MACE [hazard ratio 1.78 (95% confidence interval 1.23-2.58) per -1 U CFR and 1.53 (1.30-1.80) per +10 cm2 IMAT, adjusted P = .002 and P < .0001, respectively], while higher SM and SAT were protective [hazard ratio .89 (.81-.97) per +10 cm2 SM and .94 (.91-.98) per +10 cm2 SAT, adjusted P = .01 and .003, respectively]. Every 1% increase in fatty muscle fraction [IMAT/(SM + IMAT)] conferred an independent 2% increased odds of CMD [CFR <2, odds ratio 1.02 (1.01-1.04), adjusted P = .04] and a 7% increased risk of MACE [hazard ratio 1.07 (1.04-1.09), adjusted P < .001]. There was a significant interaction between CFR and IMAT, not BMI, such that patients with both CMD and fatty muscle demonstrated highest MACE risk (adjusted P = .02).

CONCLUSIONS

Increased intermuscular fat is associated with CMD and adverse cardiovascular outcomes independently of BMI and conventional risk factors. The presence of CMD and SM fat infiltration identified a novel at-risk cardiometabolic phenotype.

Mucosal-associated invariant T cells correlate with myocardial ischaemia and remodelling in coronary artery disease

Objectives

Myocardial ischaemia and remodelling are major contributors to the progression and mortality of coronary artery disease (CAD). Previous studies have shown immune cell alterations in CAD patients, but their characteristics and associations with myocardial ischaemia and remodelling remain unclear.

Methods

We compared immune cell changes among patients without CAD, those with CAD and those with CAD and heart failure (HF).

Results

We found a progressive reduction in circulating mucosal-associated invariant T (MAIT) cells across the three patient groups. MAIT cells exhibited increased expression of activation markers (CD69 and PD-1) and cytotoxic molecules (such as granzyme B). The features of MAIT cells were correlated positively with worsening clinical indicators of myocardial ischaemia and remodelling, including the Gensini score, cTnI, NT-proBNP, LVEF and E/e'. Additionally, the reduction, activation and cytotoxicity of MAIT cells were associated with indicators of myocardial fibrosis (sST2, Gal-3, PICP and PIIINP), a central pathological mechanism of myocardial remodelling. Finally, we preliminarily explored potential triggers for MAIT cell abnormalities in CAD patients and found that impaired intestinal barrier function and increased circulating bacterial antigens may contribute to these changes.

Conclusions

During CAD progression, we observed a decrease in circulating MAIT cells. Enhanced activation and cytotoxicity of MAIT cells are associated with myocardial ischaemia and remodelling in CAD patients with heart failure, potentially triggered by gut microbial leakage. Our findings suggest a novel strategy for monitoring and intervention in disease progression.

Temporal changes in PET myocardial flow reserve: Implications for cardiovascular outcomes

BACKGROUND

The usefulness of serial measurements of myocardial flow reserve (MFR) has received limited study outside of transplant vasculopathy. We describe the trends of myocardial blood flow and perfusion over time in patients undergoing positron emission tomography (PET) myocardial perfusion imaging (MPI) for the evaluation of coronary artery disease, and their association with cardiovascular outcomes.

METHODS

We retrospectively analyzed data from 474 patients without a history of heart transplant who underwent serial PET MPI (N = 948 studies) for the evaluation of coronary artery disease at Yale New Haven Hospital between 2016 and 2022. Patients were categorized according to MFR trajectory (low to low, low to high, high to low, high to high). Long-term major adverse cardiovascular events (MACE), defined as death or myocardial infarction, were analyzed with the Kaplan-Meier method and Cox regression. Log-likelihood, C-statistic and net reclassification were used to assess model performance.

RESULTS

The median interval time between tests was 776 days (IQR: 497-1058). The most common indications for the first and second PET were chest pain and dyspnea. MFR was similar in serial exams (2.1 [1.7, 2.6] vs 2.1 [1.7, 2.5], P = .75), but rest (1 [.8, 1.3] vs .9 [.7, 1] P < .01) and stress flows (2.1 [1.6, 2.8] vs 1.8 [1.4, 2.2], P < .01) were both reduced on the second PET. MFR increased in patients with revascularization between tests (N = 62 patients) (1.6 [1.3, 2.0] vs 1.7 [1.2, 2.2], P = .04). During a median follow-up time of 17 [8,28] months, the rate of MACE was 12% (51 events) and was higher in the low-to-low and low-to-high categories in multivariable analysis. The model including serial MFR and perfusion performed better than the baseline model including traditional clinical risk factors in terms of the likelihood ratio and C-statistic (from .74 to .80, P = .04).

CONCLUSIONS

In conclusion, our findings suggest that the serial assessment of MFR and perfusion may improve risk stratification beyond traditional clinical risk factors.

Acute Myocardial Infarction Mortality in the Older Population of the United States: An Analysis of Demographic and Regional Trends and Disparities from 1999 to 2022

Background/Objectives: Acute myocardial infarction (AMI) has been a leading cause of mortality in the US. Though AMI mortality has been decreasing in the US, significant disparities have persisted. We aim to evaluate disparities in AMI-related deaths in the US from 1999 to 2022. Methods: Data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) multiple causes of death database were used to analyze death certificates from 1999 to 2022 for AMI-related deaths among United States older adults (aged ≥ 65) for overall trend and disparities based on demographic (sex, race/ethnicity, and ten-year age groups) and regional (census regions, rural-urban status, and states) subgroups. Rural and urban status were distinguished using definitions set by the 2013 NCHS Urban-Rural Classification scheme for counties. These data come from the 2010 Census report and are updated from the 2006 NCHS Urban-Rural Classification scheme for counties. The crude mortality rate (CMR) and age-adjusted mortality rates (AAMRs) per 100,000 people were used to calculate annual percentage changes (APCs) and average annual percentage changes (AAPCs) using Joinpoint regression analysis. Results: From 1999 to 2022, there were 3,249,542 deaths due to AMI. Overall, age-adjusted mortality rates (AAMRs) decreased by 62.78% from 563.2 * (95% CI 560.3-565.7) in 1999 to a nadir at 209.6 * (208.3-210.8) in 2019, with an AAPC of -4.96 * (95% CI -5.11 to -4.81). There were a total of 355,441 deaths from AMI from 2020 to 2022; 21,216 (5.97%) of those were from AMI with COVID-19 infection. An increase of 11.4% was observed from an AAMR of 209.6 * (95% CI 208.3-210.8) in 2019 to 233.5 * (95% CI 232.2-234.8) in 2021. From 2021 to 2022, the AAMR of AMI decreased from 233.5 * (95% CI 232.2-234.8) to 209.8 * (95% CI 208.6-211), recovering to the 2019 levels. The AAMR for AMI excluding associated COVID-19 infection was 217.2 at its peak in 2021, which correlates to only a 3.63% increase from 2019. Significant disparities in AMI mortality were observed, with higher mortality rates in men, African Americans, the oldest age group (age ≥ 85), and those living in southern states and rural areas. Conclusions: AMI mortality in the older adult population of the US has significantly decreased from 1999 to 2019, with a brief increase during the pandemic from 2019 to 2021, followed by recovery back to the 2019 level in 2022. The majority of the rise observed during the pandemic was associated with COVID-19 infection. Despite remarkable improvement in mortality, significant disparities have persisted, with men, African Americans, and those living in rural areas and the southern region of the US having disproportionately higher mortality.

Angina in stable coronary artery disease: Data from ORBITA and ORBITA-2

It is now widely accepted that in the setting of stable angina, the primary remit of percutaneous coronary intervention (PCI) is for symptom relief. However, prior to the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) trial, there had been no placebo-controlled trial to assess the efficacy of this common procedure to improve angina. ORBITA randomised 200 patients with significant single-vessel coronary artery disease on maximal anti-anginal medications to either PCI or a placebo procedure. The results were striking and unexpected: after 6 weeks, there was no significant difference in the primary endpoint of treadmill exercise time between groups. Questions arose; how could PCI fail to outperform a placebo procedure, despite resolving significant epicardial stenosis and ischaemia? Clearly the relationship between symptoms, ischaemia and stenosis was more complex than previously understood. ORBITA-2 was designed to assess the effect of PCI compared to placebo in patients with single or multivessel disease, without the possible attenuation of anti-anginal medication, at 12 weeks. In this setting, PCI convincingly improved symptoms, with a significant increment over placebo as assessed by the angina symptom score, a patient-orientated primary endpoint. Taken together, these trials highlight a key insight: when offered first without anti-anginal medications, PCI offers meaningful symptom benefit. When offered after anti-anginal medications, as is recommended by international guidelines, it's added benefit is much smaller. This suggests the sequence of treatment matters, with the first therapy, whether PCI or medications, yielding the most demonstrable benefit, with subsequent interventions then offering little added value. As clinicians, the decision to advocate for PCI or anti-anginal medications first, will depend on many factors including individual patient characteristics and preferences. Importantly, in the absence of a head-to-head placebo-controlled trial of PCI alone versus medication alone, the question of which approach offers the greatest symptomatic benefit remains unresolved.

Lipid profiles and their association with incident carotid atherosclerosis: A community-based prospective study in Taiwan

BACKGROUND AND AIMS

Dyslipidemia, characterized by abnormal blood lipid levels, contributes to atherosclerosis, a condition involving arterial plaque buildup and cardiovascular events. While LDL-C and LDL-to-HDL-C ratios are established atherosclerosis predictors, the role of non-HDL-C is less explored.

METHODS AND RESULTS

A cohort of 1062 participants without carotid plaque at baseline was analyzed over a 4.0-year follow-up. Age-specific incidence rates were calculated, and baseline characteristics of those who developed plaques were compared using logistic regression and area under the ROC curve (AUROC) analysis to evaluate predictive models. Carotid plaques developed in 284 participants (87 males, 197 females). Incidence rates increased with age, reaching 41.2 % in females and 60.0 % in males aged 70-74 years. Participants with plaques were older (58.2 vs. 55.4 years, p < 0.0001), had higher BMI, blood pressure, and lipid markers, and were more likely to be male, hypertensive, or hyperlipidemic. Logistic regression identified age (OR 1.26 per 5 years), BMI (OR 1.23 per 5 kg/m2), LDL-C (OR 1.07 per 10 mg/dL), and LDL-to-HDL-C ratio (OR 1.41) as significant predictors, with HDL-C offering a protective effect. Models incorporating lipid ratios (non-HDL-to-HDL-C or LDL-to-HDL-C) showed similar predictive power (AUROC 0.636).

CONCLUSION

Carotid plaque progression correlates with age, male sex, elevated BMI, hypertension, and adverse lipid profiles. Lipid ratios and age are consistent predictors, with HDL-C demonstrating protective effects. Comparable AUROC values across models underscore the value of lipid ratios for assessing atherosclerosis risk.

Determinants of Qigong, Tai Chi, and Yoga Use for Health Conditions: A Systematic Review Protocol

INTRODUCTION

Mind-body movement interventions such as qi gong, tai chi, and yoga are recommended in clinical practice guidelines to improve outcomes for several health conditions. However, use of these interventions for health conditions, or the integration of these interventions within healthcare settings, is low. A systematic synthesis of implementation determinants (i.e., barriers and facilitators) is needed to increase adoption. Similarly, determinants may influence other implementation outcomes, such as scalability or sustainability of these interventions in a healthcare system or community organization. Thus, in conducting this review we aim to identify determinants of qi gong, tai chi, and yoga use for health conditions. The secondary aim is to evaluate whether barriers and facilitators differ by intervention type, health condition, implementation setting, or implementation outcome.

METHODS AND ANALYSIS

We conducted a comprehensive search of electronic databases (MEDLINE, EMBASE, Web of Science, CINAHL, PsycInfo) through May 2024 and a grey literature search (Google Scholar, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov , the WHO Clinical Trials database) through March 2025. We will include original research articles in English that identify barriers and facilitators to adoption of qi gong, tai chi, and yoga by adults with health conditions. Study quality will be assessed using the Mixed Methods Appraisal Tool. We will code each article using a codebook informed by the Consolidated Framework for Implementation Research (CFIR), a comprehensive taxonomy of implementation determinants. Findings will be presented as a narrative synthesis. We will report on how barriers and facilitators may relate to intervention type (qi gong, tai chi, yoga), health condition (e.g., low back pain, fall prevention), implementation settings (e.g., primary care clinic, community organization) or implementation outcome (e.g., adoption, sustainability).

ETHICS AND DISSEMINATION

Ethics approval will not be obtained for this review of published, publicly accessible data. The results from this systematic review will be disseminated through conference presentations and journal publications.

STRENGTHS AND LIMITATIONS OF THIS STUDY

There are no prior comprehensive reviews of the determinants (i.e., barriers and facilitators) of qi gong, tai chi and yoga use. This review will examine whether barriers and/or facilitators vary by type of mind-body movement intervention, health condition, implementation setting, or implementation outcome.Our search has been guided by librarians with expertise in systematic review methodology and informed by the PEER Review of Electronic Search Strategies (PRESS) guidelines. Reporting of results will be informed by the PRISMA-P checklist for systematic reviews.We will use the updated version of the Consolidated Framework for Implementation Research (CFIR, version 2.0) to report implementation factors using consistent concepts to facilitate use of the review by researchers, healthcare systems, and community organizations. Our findings will support the development of implementation strategies to increase the adoption of qi gong, tai chi, and yoga for health conditions.Due to the complex nature of describing implementation determinants and characterizing them within the Consolidated Framework for Implementation Research, our review is limited to papers written in English which may restrict the generalizability of our implementation findings to predominantly English-speaking healthcare settings.

Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology

COLLABORATORS

Larry A. Allen, MD, MHS, FAHA, FACC; Mats Börjesson, MD, PhD, FACC; Alan C. Braverman, MD, FACC; Julie A. Brothers, MD; Silvia Castelletti, MD, MSc, FESC; Eugene H. Chung, MD, MPH, FHRS, FAHA, FACC; Timothy W. Churchill, MD, FACC; Guido Claessen, MD, PhD; Flavio D'Ascenzi, MD, PhD; Douglas Darden, MD; Peter N. Dean, MD, FACC; Neal W. Dickert, MD, PhD, FACC; Jonathan A. Drezner, MD; Katherine E. Economy, MD, MPH; Thijs M.H. Eijsvogels, PhD; Michael S. Emery, MD, MS, FACC; Susan P. Etheridge, MD, FHRS, FAHA, FACC; Sabiha Gati, BSc (Hons), MBBS, PhD, MRCP, FESC; Belinda Gray, BSc (Med), MBBS, PhD; Martin Halle, MD; Kimberly G. Harmon, MD; Jeffrey J. Hsu, MD, PhD, FAHA, FACC; Richard J. Kovacs, MD, FAHA, MACC; Sheela Krishnan, MD, FACC; Mark S. Link, MD, FHRS, FAHA, FACC; Martin Maron, MD; Silvana Molossi, MD, PhD, FACC; Antonio Pelliccia, MD; Jack C. Salerno, MD, FACC, FHRS; Ankit B. Shah, MD, MPH, FACC; Sanjay Sharma, BSc (Hons), MBChB, MRCP (UK), MD; Tamanna K. Singh, MD, FACC; Katie M. Stewart, NP, MS; Paul D. Thompson, MD, FAHA, FACC; Meagan M. Wasfy, MD, MPH, FACC; Matthias Wilhelm, MD.

This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international experts in sports cardiology and the respective topics covered were assigned to each section and prepared specific clinical considerations tables for practitioners to reference. Comprehensive literature review and an emphasis on shared decision-making were integral in the writing of all clinical considerations presented.

Persistent Beta-Blocker Therapy Reduces Long-Term Mortality in Patients With Acute Ischemic Stroke With Elevated Heart Rates

BACKGROUND

Elevated heart rate in patients with acute ischemic stroke is associated with increased risk of mortality. Beta-blocker therapy is well known to reduce heart rate.

METHODS AND RESULTS

This study was a post hoc analysis of patients with acute ischemic stroke with maximum heart rates ≥100 bpm. Beta-blocker use, assessed on the eighth day after the index stroke, was categorized as persistent or nonpersistent based on usage up to 39 months. The primary outcome was a composite of stroke recurrence, myocardial infarction, and mortality within the first year. Long-term mortality, a secondary outcome, was tracked for up to 10 years. Among 5049 patients (women, 38%; mean age, 68.5 years), 32.1% were prescribed beta blockers by the eighth day after stroke, and 99% had prior beta-blocker use. One-year cumulative incidences of the primary outcome, stroke recurrence, and death were 27.8%, 3.5%, and 25.8%, respectively. Persistent beta-blocker use was associated with a significant reduction in the primary outcome (adjusted hazard ratio [HR], 0.81 [95% CI, 0.68-0.97]) and mortality (adjusted HR, 0.80 [95% CI, 0.69-0.94]) from 2 months to 1 year. Extended analysis of mortality for up to 10 years showed long-term benefits of beta-blocker use. Analyses subdividing patients into persistent users, discontinuers, and never-users suggested higher early mortality risk among discontinuers and potential late survival benefits for persistent users. Subgroup analyses demonstrated greater benefits in patients <75 years, and those with atrial fibrillation, coronary heart disease, and higher mean heart rates.

CONCLUSIONS

Our study shows that continuation of beta-blocker therapy in patients with acute ischemic stroke with tachycardia significantly reduces long-term mortality.

Markers of inflammation predicts long-term mortality in patients with acute coronary syndrome - a cohort study

BACKGROUND

Chronic low-grade inflammation is a well-known risk factor for coronary heart disease (CHD) and future cardiovascular events. Anti-inflammatory therapy can reduce the risk of ischemic cardiovascular disease (CVD) events following myocardial infarction (MI). However, it remains unknown to what extent inflammation at the time of an acute event predicts long-term outcomes. We explored whether routine blood measurements of inflammatory markers during an acute coronary syndrome (ACS) are predictive of long-term mortality.

METHODS

In a cohort of 5292 consecutive patients admitted to a coronary intensive care unit with suspected ACS over a four-year period in the Carlscrona Heart Attack Prognosis Study (CHAPS), 908 patients aged 30-74 years (644 men, 264 women) were diagnosed with MI (527) or unstable angina (UA) (381). A 10-year follow-up study was conducted using Swedish national registries, with total mortality and cardiac mortality as primary outcomes.

RESULTS

Long-term total and cardiac mortality were significantly associated with higher leukocyte counts (e.g., neutrophils, monocytes, p ≤ 0.001), higher levels of inflammatory biomarkers (e.g., C-reactive protein, Serum Amyloid A, fibrinogen, p ≤ 0.001), and elevated neutrophil-lymphocyte ratio (NLR) (p < 0.001) and monocyte-lymphocyte ratio (MLR) (p = 0.002), all measured at ACS admission. These associations were independent of ACS diagnosis.

CONCLUSION

Our results suggest that level of inflammation at ACS presentation-beyond its established role as a major CHD risk factor-also predicts long-term mortality following ACS. Notably, inflammation at the time of the event was a stronger predictor of long-term mortality than the acute event outcome itself. However, limitations include the observational study design, moderate sample size, and absence of modern high-sensitivity cardiac biomarkers and contemporary ACS management strategies in this cohort. The results should therefore be interpreted in the context of historical clinical practice. While our model-wise complete-case approach ensured consistency, missing data remains a potential source of bias. Future studies in larger, more contemporary cohorts are needed to validate these findings and refine risk stratification strategies.

Research of affordability to essential medicines for coronary heart disease in Ukraine

Background

The issue of population access to medicines is relevant worldwide. Pandemics, natural disasters, wars negatively affect the population's access to medicines, as emphasised by the WHO and the UN.

Methods

The analysis of scientific publications in the Ukrainian scientometric databases (NRAT, OUCI); Scopus, Web of Science, Pubmed, Medline, BMJ and Embase; the legal field for providing medical care to patients with CHD and comorbid conditions and its pharmaceutical component. The EML of Europe and Ukraine are compared; the clinical recommendations and pharmacotherapy of European/American Societies of Cardiology (ESC/AHA) and Ukrainian for patients with CHD and comorbid conditions are compared.

Results

The prices of medicines that are not part of the 'Affordable Medicines' program and are included in the EML lists were analysed; their availability for Ukrainian patients in wartime conditions was determined. The legal field of providing medical care to patients with CHD and comorbid conditions has been formed. It was established that not all medicines specified in the EML are registered on the territory of Ukraine and included in the Program of Medical Guarantees (PMG).

Conclusion

The PMG includes most of the EML medicines. The modern pharmacotherapy of CHD and comorbid conditions has a positive impact on the budget of the health care system in clinical practice proposed by the ESC/AHA was determined. The lists of medicines in the PMG in Ukraine, need to be revised on the basis of the Health Technology Assessment for further inclusion in the state program 'Affordable Medicines' for long-term use by patients with CHD and comorbid conditions. These measures will improve the quality of pharmaceutical care for these patients.

Prevalence and Clinical Outcomes of Discordant Lesions Between Fractional Flow Reserve and Nonhyperemic Pressure Ratios in Clinical Practice: The J-PRIDE Registry

BACKGROUND

Limited large-scale, real-world data exist on the prevalence and clinical impact of discordance between fractional flow reserve (FFR) and nonhyperemic pressure ratios (NHPRs).

METHODS

The J-PRIDE registry (Clinical Outcomes of Japanese Patients With Coronary Artery Disease Assessed by Resting Indices and Fractional Flow Reserve: A Prospective Multicenter Registry) prospectively enrolled 4304 lesions in 3200 patients from 20 Japanese centers. The lesions were classified into FFR+/NHPR-, FFR-/NHPR+, FFR+/NHPR+, or FFR-/NHPR groups according to cutoff values of 0.89 for NHPRs and 0.80 for FFR. The primary study end point was the cumulative 1-year incidence of target vessel failure (a composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization) on a lesion basis.

RESULTS

An NHPR cutoff value of 0.89, determined using online software, predicted an FFR of 0.80 across various NHPR types. Discordance between FFR and NHPRs was observed in 20% of lesions (FFR+/NHPR-, 11.2%; FFR-/NHPRs+, 8.8%). Revascularization was deferred in 42.9% and 88.4% of the FFR+/NHPR- and FFR-/NHPR+ groups, respectively. In deferred vessels, the FFR+/NHPR- and FFR-/NHPR+ groups showed a higher 1-year incidence of target vessel failure compared with the FFR-/NHPR- group (7.9% versus 5.5% versus 1.7%; for FFR+/NHPR-, adjusted hazard ratio [aHR], 4.89 [95% CI, 2.68-8.91]; P<0.001; for FFR-/NHPR+, aHR, 2.64 [95% CI, 1.49-4.69]; P<0.001). In revascularized vessels, the 1-year target vessel failure rate was numerically higher in the FFR-/NHPR+ group than in the FFR+/NHPR+ group (9.6% versus 3.4%; aHR, 2.27 [95% CI, 0.70-7.34]; P=0.17), although with similar outcomes between the FFR+/NHPR- and FFR+/NHPR+ groups (2.3% versus 3.4%; aHR, 0.96 [95% CI, 0.37-2.38]; P=0.93). The FFR+/NHPR- group benefited from revascularization compared with medical treatment (aHR, 0.26 [95% CI, 0.08-0.86]; P=0.027); the FFR-/NHPR+ group did not (aHR, 2.39 [95% CI, 0.62-9.21]; P=0.20).

CONCLUSIONS

Discordance between FFR and NHPRs was noted in 20% of lesions, and discordant deferred lesions resulted in worse outcomes than concordant negative lesions. Although the outcomes after deferring revascularization were comparable between the FFR+/NHPR- and FFR-/NHPR+ lesions, only FFR+/NHPR- lesions showed a benefit from revascularization compared with medical treatment, suggesting that an FFR-guided strategy is superior to an NHPR-guided strategy in discordant lesions.

REGISTRATION

URL: https://www.umin.ac.jp; Unique identifier: UMIN000038403.

Remnant cholesterol, lipid ratios, and the severity of coronary artery lesions: a retrospective cohort study in patients with coronary heart disease

Background

Emerging genetic and observational evidence indicates that remnant cholesterol (RC) is a significant residual risk factor for cardiovascular diseases. However, there is a relative paucity of evidence exploring the correlation among RC, lipid ratios, and atherosclerotic lesion severity. This study aimed to investigate the predictive value of RC and lipid ratios alone or in combination for the severity of coronary artery stenosis in patients with coronary heart disease (CHD).

Methods

The Gensini score was used to assess the severity of coronary atherosclerotic lesions. CHD patients were categorized into mild stenosis and moderate-to-severe stenosis groups. Logistic regression was used to evaluate the risk of a high Gensini score associated with RC and lipid ratios. Our study also examined the relationship between inconsistencies in RC and non-high-density lipoprotein cholesterol (non-HDL-C) levels and the severity of coronary artery stenosis. Receiver operating characteristic (ROC) curves were used to assess the predictive power of RC and lipid ratios alone or in combination for moderate to severe coronary artery lesions.

Results

Multivariate regression models suggested that RC was a strong predictor of moderate to severe coronary artery stenosis [odds ratio (OR): 5.44, P < 0.001]. When grouped by curve-fitting inflection points, the group with inconsistent high RC/low non-HDL-C, rather than the low RC/high non-HDL-C group, was associated with an increased risk of moderate to severe coronary stenosis compared with the consistent low RC group (OR: 2.72, P < 0.001). ROC curves showed that RC predicted an area under the curve (AUC) of 0.715 for coronary stenosis severity, improving the predictive efficacy of the combined predictors comprising lipid ratios (AUC: 0.723 vs. 0.703, P < 0.05).

Conclusions

RC and various lipid ratios [triglyceride/HDL-C, total cholesterol/HDL-C, low-density lipoprotein cholesterol/HDL-C, and apoloprotein (apo)B/apoA] correlated with the degree of coronary artery stenosis in patients with CHD, suggesting that RC has potential value as a biomarker reflecting the degree of coronary artery stenosis independent of the traditional risk factors and the levels of non-HDL-C. This could enhance the predictive efficacy based on the lipid ratio model and had better predictive value for moderate to severe coronary artery lesions.

Prevalence of Depression, Anxiety and Post-Traumatic Stress Disorder (PTSD) After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

Background: Mental illnesses following an acute myocardial infarction (AMI) are a growing concern, as they are associated with worse outcomes for AMI patients. Our understanding of the prevalence of mental illnesses after an AMI is incomplete, as most studies investigate depression while overlooking other conditions like anxiety and PTSD. Existing studies often rely on patient-reported questionnaires for mental illness diagnoses, a method that can be subjective. To address this, we conducted a systematic review and meta-analysis to determine the prevalence and risk factors of depression, anxiety, and PTSD after AMI, including only studies with formal mental illness diagnoses. Methods: Searches in MEDLINE, EMBASE, and PsycINFO up to 23 January 2025 identified 23 qualifying studies that assessed the prevalence of depression, anxiety, and PTSD after AMI, with cases defined exclusively by formal diagnoses established through psychiatrist-administered structured interviews according to the Diagnostic and Statistical Manual for Mental Disorders (DSM) criteria (versions III to V). For each outcome, the pooled prevalence was estimated using meta-analyses of proportions with random-effects models. If significant heterogeneity was detected, subgroup analyses and meta-regression were performed to explore the factors contributing to this heterogeneity. Results: A total of 25 studies were included in the meta-analysis. Among the 20 studies included, the pooled prevalence of depression after AMI was 23.58% (95% CI: 22.86%; 24.32%). When stratified by time since AMI, the prevalence was 19.46% (95% CI: 15.47%; 24.19%) for those assessed within 3 months and 14.87% (95% CI: 9.55%; 22.43%) for those assessed after 3 months. The pooled prevalence of anxiety (seven studies) and PTSD (three studies) was 11.96% (95% CI: 6.15; 21.96%) and 10.26% (95% CI: 5.49%; 18.36%), respectively. Further pooled prevalence subgroup analysis of depression and anxiety revealed significantly higher rates in the female sex (29.89%, 95% CI: 21.85; 39.41%), in those with hypertension (25.01%, 95% CI: 21.68; 28.67%), diabetes (25.01%, 95% CI: 21.68; 28.67%), or hyperlipidemia (28.96% 95% CI: 23.44; 35.17%), and in smokers (25.23%., 95% CI: 19.48; 32.00%), while the pooled prevalence of depression is higher in unmarried (35.44%, 95% CI: 19.61; 55.26%) than married individuals (28.63%, 95% CI: 18.67; 41.20%) and in those with a history of depression (57.41%, 95% CI: 31.47; 78.92%). The results of the meta-regression indicated that a prior history of depression was a significant predictor of depression prevalence (p = 0.0035, regression coefficient 1.54). Conclusions: The prevalence of mental illnesses, including depression, anxiety, and PTSD, is notable following an AMI. Identified risk factors encompass female sex, hypertension, diabetes mellitus, hyperlipidemia, smoking, a history of depressive illness, and social context.

Precision Medicine in Cardiovascular Disease Prevention: Clinical Validation of Multi-Ancestry Polygenic Risk Scores in a U.S. Cohort

BACKGROUND

Polygenic risk score (PRS) quantifies the cumulative effects of common genetic variants across the genome, including both coding and non-coding regions, to predict the risk of developing common diseases. In cardiovascular medicine, PRS enhances risk stratification beyond traditional clinical risk factors, offering a precision medicine approach to coronary artery disease (CAD) prevention. This study evaluates the predictive performance of a multi-ancestry PRS framework for cardiovascular risk assessment using the All of Us (AoU) short-read whole-genome sequencing dataset comprising over 225,000 participants.

METHODS

We developed PRSs for lipid traits (LDL-C, HDL-C, triglycerides) and cardiometabolic conditions (type 2 diabetes, hypertension, atrial fibrillation) and constructed two metaPRSs: one integrating lipid and cardiometabolic PRSs (risk factor metaPRS) and another incorporating CAD PRSs in addition to these risk factors (risk factor + CAD metaPRS). Predictive performance was evaluated separately for each trait-specific PRS and for both metaPRSs to assess their effectiveness in CAD risk prediction across diverse ancestries. Model predictive performance, including calibration, was assessed separately for each ancestry group, ensuring that all metrics were ancestry-specific and that PRSs remain generalizable across diverse populations Results: PRSs for lipids and cardiometabolic conditions demonstrated strong predictive performance across ancestries. The risk factors metaPRS predicted CAD risk across multiple ancestries. The addition of a CAD-specific PRS to the risk factors metaPRS improved predictive performance, highlighting a genetic component in CAD etiopathology that is not fully captured by traditional risk factors, whether clinically measured or genetically inferred. Model calibration and validation across ancestries confirmed the broad applicability of PRS-based approaches in multi-ethnic populations.

CONCLUSION

PRS-based risk stratification provides a reliable, ancestry-inclusive framework for personalized cardiovascular disease prevention, enabling better targeted interventions such as pharmacological therapy and lifestyle modifications. By incorporating genetic information from both coding and non-coding regions, PRSs refine risk prediction across diverse populations, advancing the integration of genomics into precision medicine for common diseases.

Estimates and projections in the economic impacts of fifteen dietary risk factors for two hundred four countries and territories from 2020 to 2050: A health-augmented macroeconomic modeling study

BACKGROUND

Suboptimal diet results in significant health and economic burdens. However, the global economic costs of dietary risks remain unclear.

OBJECTIVES

This study aimed to estimate the macroeconomic burden of 15 dietary risk factors in 204 countries and territories from 2020 to 2050.

METHODS

This health-augmented macroeconomic modeling study assessed the macroeconomic burden that accounted for the decrease in labor supply across different education levels due to mortality and morbidity, as well as the impact of healthcare expenses on investment and savings. Country-specific data were drawn from publicly accessible databases. The cumulative difference in the aggregate output between a realistic scenario without intervention and a counterfactual scenario assuming complete disease elimination was quantified as the macroeconomic burden attributable to diseases. The proportion of disease burden attributed to dietary risk factors was quantified using population-attributable fractions derived from the global burden of disease study 2019, which was integrated into the health-augmented macroeconomic model. Estimates were converted to 2017 international dollars (INT $).

RESULTS

The estimated global macroeconomic burden attributable to dietary risks from 2020 to 2050 was INT $15,491 [uncertainty interval 13078, 18742] billion, representing 0.34% (uncertainty interval 0.29%, 0.41%) of the total gross domestic product. The macroeconomic burden was unevenly distributed across countries, regions, income groups, disease types, and dietary risk factors. The United States (INT $3972 billion), China (INT $2764 billion), and India (INT $1300 billion) had the largest macroeconomic burden. Ischemic heart disease (INT $9384 billion), diabetes (INT $2392 billion), and stroke (INT $1954 billion) accounted for ∼90% of the overall macroeconomic burden. A diet low in whole grains (INT $3808 billion) incurred the highest cost, followed by a diet high in sodium (INT $2812 billion) and red meat (INT $2337 billion).

CONCLUSIONS

The global macroeconomic burden attributable to dietary risks was substantial and varied across countries, regions, income groups, disease types, and individual dietary risk factors.